 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The researchers noted that the study had a number of limitations -- breast cancer risk factors weren't assessed and detailed analyses weren't conducted on primary tumors. The study authors also said the profile of future groups of breast cancer patients may differ from that of those in this study. For example, tamoxifen use might not be as widespread or patients might be undergoing adjuvant systemic therapy.
Nevertheless, the study authors concluded, "There are insufficient data to establish the safety of tibolone in women who have had breast cancer and do not require or have finished adjuvant therapy."
This is just the latest study to raise concerns about tibolone. A U.S. study released last summer found that women 60 and older who took tibolone to relieve menopausal symptoms were 2.2 times more likely to suffer a stroke than those taking a placebo. The finding prompted an early halt to that study, which was published in the New England Journal of Medicine.
Text Continues Below
But that same study also found that women taking tibolone had a reduced risk of breast cancer and colon cancer.
More information
The U.S. National Women's Health Information Center has more about menopause treatment
Page: << Prev | 1 | 2
-- Robert Preidt
|
.gif)
